Search research articles
Contact Us
Filters
Showing results (71-80 of 450) with videos related to
Page
of 45
Sort By:
Neuro-Oncology Advances
|
September 20, 2023
Loss of H3K27me3 in meningiomas: an independent marker for CNS WHO grade 2?
Felix Behling, Peter Paßlack, Christina-Katharina Fodi, et al.
European Radiology
|
September 9, 2024
Shape matters: unsupervised exploration of IDH-wildtype glioma imaging survival predictors
Martha Foltyn-Dumitru, Mustafa Ahmed Mahmutoglu, Gianluca Brugnara, et al.
Neuro-Oncology
|
March 20, 2025
Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: implications for clinical outcomes
Martha Foltyn-Dumitru, Rouzbeh Banan, Marianne Schell, et al.
European Radiology
|
May 26, 2025
Optimizing MRI sequence classification performance: insights from domain shift analysis
Mustafa Ahmed Mahmutoglu, Aditya Rastogi, Gianluca Brugnara, et al.
Neuropathology and Applied Neurobiology
|
May 24, 2024
Accurate and comprehensive evaluation of O6-methylguanine-DNA methyltransferase promoter methylation by nanopore sequencing
Skarphedinn Halldorsson, Richard Mark Nagymihaly, Areeba Patel, et al.
Brain Pathology (Zurich, Switzerland)
|
November 15, 2022
Clinical implementation of integrated molecular-morphologic risk prediction for meningioma
Thomas Hielscher, Martin Sill, Philipp Sievers, et al.
Acta Neuropathologica Communications
|
October 24, 2023
Refinement of diagnostic criteria for pediatric-type diffuse high-grade glioma, IDH- and H3-wildtype, MYCN-subtype including histopathology, TP53, MYCN and ID2 status
Arnault Tauziède-Espariat, Emmanuelle Uro-Coste, Yvan Nicaise, et al.
Neuropathology and Applied Neurobiology
|
November 27, 2021
AKT1<sup>E17K</sup> -mutated meningioma cell lines respond to treatment with the AKT inhibitor AZD5363
Peter John, Natalie Waldt, Josephine Liebich, et al.
Oncoimmunology
|
August 17, 2017
K27M-mutant histone-3 as a novel target for glioma immunotherapy
Katharina Ochs, Martina Ott, Theresa Bunse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2011
Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness
Dieter Lemke, Philipp-Niclas Pfenning, Felix Sahm, et al.
Page
of 45
Search research articles
Search
Showing results (71-80 of 450) with videos related to
Sort By:
Page
of 45
Neuro-Oncology Advances
|
September 20, 2023
Loss of H3K27me3 in meningiomas: an independent marker for CNS WHO grade 2?
Felix Behling, Peter Paßlack, Christina-Katharina Fodi, et al.
European Radiology
|
September 9, 2024
Shape matters: unsupervised exploration of IDH-wildtype glioma imaging survival predictors
Martha Foltyn-Dumitru, Mustafa Ahmed Mahmutoglu, Gianluca Brugnara, et al.
Neuro-Oncology
|
March 20, 2025
Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: implications for clinical outcomes
Martha Foltyn-Dumitru, Rouzbeh Banan, Marianne Schell, et al.
European Radiology
|
May 26, 2025
Optimizing MRI sequence classification performance: insights from domain shift analysis
Mustafa Ahmed Mahmutoglu, Aditya Rastogi, Gianluca Brugnara, et al.
Neuropathology and Applied Neurobiology
|
May 24, 2024
Accurate and comprehensive evaluation of O6-methylguanine-DNA methyltransferase promoter methylation by nanopore sequencing
Skarphedinn Halldorsson, Richard Mark Nagymihaly, Areeba Patel, et al.
Brain Pathology (Zurich, Switzerland)
|
November 15, 2022
Clinical implementation of integrated molecular-morphologic risk prediction for meningioma
Thomas Hielscher, Martin Sill, Philipp Sievers, et al.
Acta Neuropathologica Communications
|
October 24, 2023
Refinement of diagnostic criteria for pediatric-type diffuse high-grade glioma, IDH- and H3-wildtype, MYCN-subtype including histopathology, TP53, MYCN and ID2 status
Arnault Tauziède-Espariat, Emmanuelle Uro-Coste, Yvan Nicaise, et al.
Neuropathology and Applied Neurobiology
|
November 27, 2021
AKT1<sup>E17K</sup> -mutated meningioma cell lines respond to treatment with the AKT inhibitor AZD5363
Peter John, Natalie Waldt, Josephine Liebich, et al.
Oncoimmunology
|
August 17, 2017
K27M-mutant histone-3 as a novel target for glioma immunotherapy
Katharina Ochs, Martina Ott, Theresa Bunse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 15, 2011
Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness
Dieter Lemke, Philipp-Niclas Pfenning, Felix Sahm, et al.
Page
of 45